FDA issues temporary policy for monitoring onsite activities during COVID-19
While certain monitoring requirements can be done remotely, the FDA has noted that it recognises it may be temporarily impractical to conduct certain onsite monitoring activities.
The US Food and Drug Administration (FDA) has issued guidance to communicate its temporary policy regarding certain requirements under the FDA Food Safety Modernization Act (FSMA) Accredited Third-Party Certification Program for foreign food entities and their products.
The guidance addresses the current challenges with conducting onsite monitoring activities during the COVID-19 public health emergency by providing temporary flexibility so that recognised accreditation bodies (ABs) can maintain the accreditations of certification bodies (CBs), and so that already-issued certifications need not lapse, where certain safeguards are in place.
Recognised ABs are required to monitor the CBs they accredit through a comprehensive assessment of their performance, which includes: a review of the CB’s self-assessment; its regulatory audit reports; notifications submitted to the FDA; onsite observations of regulatory audits performed by the CB; and a visit to the CB’s headquarters no later than one year after the initial date of accreditation and every two years thereafter for the duration of the CB’s accreditation.
In addition, CB’s accredited under the Accredited Third-Party Certification Program are responsible for conducting regulatory audits when certifying that eligible foreign entities are in compliance with the applicable food safety requirements of the Food, Drug, and Cosmetic Act and FDA regulations. These certifications can be used by importers for participation in the Voluntary Qualified Importer Program, and for import certification when required. These certificates are issued for a term of up to 12 months, and issuing a recertification requires an accredited to CB conduct a new audit.
For certificates that have already been issued (and that therefore have an upcoming expiration date), the FDA has reiterated that it understands current travel restrictions and advisories related to COVID-19 may hinder the ability of accredited CBs to conduct the onsite regulatory audits needed to recertify the foreign entity. Therefore, for already-issued certificates, the agency does not intend to enforce the requirement that the accredited CBs issue the certificates for a term only up to 12 months, in certain circumstances.